KR102949236B1 - 방광암의 치료 방법 - Google Patents

방광암의 치료 방법

Info

Publication number
KR102949236B1
KR102949236B1 KR1020197033495A KR20197033495A KR102949236B1 KR 102949236 B1 KR102949236 B1 KR 102949236B1 KR 1020197033495 A KR1020197033495 A KR 1020197033495A KR 20197033495 A KR20197033495 A KR 20197033495A KR 102949236 B1 KR102949236 B1 KR 102949236B1
Authority
KR
South Korea
Prior art keywords
individual
administered
oncolytic virus
virus
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197033495A
Other languages
English (en)
Korean (ko)
Other versions
KR20190134786A (ko
Inventor
아서 콴
Original Assignee
씨지 온콜로지, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨지 온콜로지, 인크. filed Critical 씨지 온콜로지, 인크.
Publication of KR20190134786A publication Critical patent/KR20190134786A/ko
Application granted granted Critical
Publication of KR102949236B1 publication Critical patent/KR102949236B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020197033495A 2017-04-14 2018-04-13 방광암의 치료 방법 Active KR102949236B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762485805P 2017-04-14 2017-04-14
US62/485,805 2017-04-14
US201762500729P 2017-05-03 2017-05-03
US62/500,729 2017-05-03
PCT/US2018/027549 WO2018191654A1 (en) 2017-04-14 2018-04-13 Methods of treating bladder cancer

Publications (2)

Publication Number Publication Date
KR20190134786A KR20190134786A (ko) 2019-12-04
KR102949236B1 true KR102949236B1 (ko) 2026-04-08

Family

ID=63792825

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033495A Active KR102949236B1 (ko) 2017-04-14 2018-04-13 방광암의 치료 방법

Country Status (9)

Country Link
US (4) US11338003B2 (https=)
EP (2) EP4599893A3 (https=)
JP (4) JP2020516590A (https=)
KR (1) KR102949236B1 (https=)
CN (1) CN110573624A (https=)
AU (1) AU2018251987B2 (https=)
ES (1) ES3030923T3 (https=)
PL (1) PL3610026T3 (https=)
WO (1) WO2018191654A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer
EP3708657A4 (en) * 2017-11-08 2021-08-25 Kagoshima University ONCOLYTIC VIRUS (ONCOLYTIC IMMUNOTHERAPY) THAT IS CAPABLE OF TREATING METASTATIC CANCER ALSO WITH ENSURED SAFETY, WITH EXPRESSION CONTROL SYSTEM THAT BUILDS AN OPTIMAL EXPRESSION LEVEL
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CN113748124A (zh) 2019-02-27 2021-12-03 阿克蒂姆治疗有限公司 工程化以定植肿瘤、肿瘤驻留免疫细胞和肿瘤微环境的免疫刺激性细菌
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
WO2022036159A2 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
CA3235418A1 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2025251009A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent
WO2025251014A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods and compositions for biomarker-guided bladder cancer therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2002514074A (ja) 1997-03-03 2002-05-14 セル ジェネシス，インコーポレイティド 異種転写調節エレメントを含有するアデノウイルスベクターおよびその使用方法
US6432700B1 (en) 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU2003252891B2 (en) 1998-09-10 2006-06-01 Cold Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
AU2001247648B2 (en) 2000-03-24 2006-03-30 Cold Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
JP2004501631A (ja) 2000-06-28 2004-01-22 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｐｄ−ｌ２分子：新規ｐｄ−１リガンドおよびその使用
BR0309254A (pt) 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7459154B2 (en) 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US20050282280A1 (en) 2003-08-28 2005-12-22 Ennist David L Oncolytic adenoviral vectors encoding GM-CSF
WO2005030261A1 (en) 2003-08-28 2005-04-07 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
TW200607859A (en) 2004-08-23 2006-03-01 Cell Genesys Inc Oncolytic adenoviral vectors encoding GM-CSF
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
DK2650020T3 (en) 2005-05-06 2017-01-16 Providence Health & Services - Oregon Trimeric OX40 immunoglobulin fusion protein and methods for applications.
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
US8557257B2 (en) 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
HRP20170165T1 (hr) 2008-12-22 2017-04-07 Targovax Oy Onkolitički adenovirusni vektori i metode i uporabe u vezi s time
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
BR112012000536A2 (pt) 2009-07-08 2020-08-11 Kymab Limited métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico
KR20130108371A (ko) 2010-09-24 2013-10-02 온코스 테라퓨틱스 오와이 단클론 항―ｃｔｌａ－４ 항체를 암호화하는 종양분해 아데노바이러스 벡터
US9056133B2 (en) 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CA2877414A1 (en) 2012-07-30 2014-02-06 Alex Wah Hin Yeung Live and in-vivo tumor specified cancer vaccine system
ES3011466T3 (en) 2013-04-18 2025-04-07 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CA2931322A1 (en) 2013-11-22 2015-05-28 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
AU2015289081B2 (en) 2014-07-16 2020-02-06 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US10583198B2 (en) * 2015-03-12 2020-03-10 Viventia Bio Inc. Dosing strategies for targeting EPCAM positive bladder cancer
JP6954648B2 (ja) * 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
PL3426271T3 (pl) 2016-03-10 2025-11-24 Cg Oncology, Inc. Sposoby leczenia guzów litych terapią skojarzoną
AU2018251987B2 (en) 2017-04-14 2024-11-28 Cg Oncology, Inc. Methods of treating bladder cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Clinical Oncology (2012) vol. 30, No. 15, Supp. SUPPL. 1. Abstract Number:4593 (2012.05.20.) 1부.*

Also Published As

Publication number Publication date
US20220296658A1 (en) 2022-09-22
JP2024028541A (ja) 2024-03-04
US20210085734A1 (en) 2021-03-25
ES3030923T3 (en) 2025-07-02
US20260014218A1 (en) 2026-01-15
PL3610026T3 (pl) 2025-07-28
EP3610026B1 (en) 2025-05-14
EP3610026A1 (en) 2020-02-19
EP4599893A3 (en) 2025-11-05
JP7597384B2 (ja) 2024-12-10
JP2026042875A (ja) 2026-03-11
US20220331384A1 (en) 2022-10-20
CN110573624A (zh) 2019-12-13
EP3610026A4 (en) 2021-03-24
JP2022164776A (ja) 2022-10-27
WO2018191654A1 (en) 2018-10-18
US11338003B2 (en) 2022-05-24
EP4599893A2 (en) 2025-08-13
US11596660B2 (en) 2023-03-07
AU2018251987A1 (en) 2019-12-05
JP2020516590A (ja) 2020-06-11
US12370229B2 (en) 2025-07-29
AU2018251987B2 (en) 2024-11-28
KR20190134786A (ko) 2019-12-04
NZ759184A (en) 2025-06-27

Similar Documents

Publication Publication Date Title
KR102949236B1 (ko) 방광암의 치료 방법
US12090183B2 (en) Methods of treating solid or lymphatic tumors by combination therapy
US20220125864A1 (en) Methods of treating solid or lymphatic tumors by combination therapy
EP3324988B1 (en) Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer
HK40022407A (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
HK40022407B (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
HK1255016B (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)